Publication: Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
dc.contributor.author | Kılıçkap, S. | |
dc.contributor.author | Öztürk, A. | |
dc.contributor.author | Karadurmuş, N. | |
dc.contributor.author | Korkmaz, T. | |
dc.contributor.author | Yumuk, P. | |
dc.contributor.author | Cicin, I. | |
dc.contributor.author | Paydaş, S. | |
dc.contributor.author | Cilbir, E. | |
dc.contributor.author | Sakalar, T. | |
dc.contributor.author | Uysal, M. | |
dc.contributor.author | Uskent, N. | |
dc.contributor.author | Demir, N. | |
dc.contributor.author | Sakin, A. | |
dc.contributor.author | Turhal, N. | |
dc.contributor.author | Keskin, S. | |
dc.contributor.author | Tural, D. | |
dc.contributor.author | Eralp, Y. | |
dc.contributor.author | Basal, F. | |
dc.contributor.author | Yaşar, H. | |
dc.contributor.author | Sendur, M. A. | |
dc.contributor.author | Demirci, U. | |
dc.contributor.author | Çubukcu, Erdem | |
dc.contributor.author | Karaağaç, M. | |
dc.contributor.author | Karaca, S. | |
dc.contributor.author | Tatlı, A. | |
dc.contributor.author | Yetişyiğit, T. | |
dc.contributor.author | Urvay, S. | |
dc.contributor.author | Gürsoy, P. | |
dc.contributor.author | Uluc, B. Oyan | |
dc.contributor.author | Turna, Z. | |
dc.contributor.author | Küçükoner, M. | |
dc.contributor.author | Çlmez, O. | |
dc.contributor.author | Çabuk, D. | |
dc.contributor.author | Şeker, M. | |
dc.contributor.author | Ünal, O. | |
dc.contributor.author | Meydan, N. | |
dc.contributor.author | Okutur, S. | |
dc.contributor.author | Tunalı, D. | |
dc.contributor.buuauthor | ÇUBUKÇU, ERDEM | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi | |
dc.contributor.researcherid | JGT-4101-2023 | |
dc.date.accessioned | 2024-07-25T11:26:14Z | |
dc.date.available | 2024-07-25T11:26:14Z | |
dc.date.issued | 2018-10-01 | |
dc.identifier.eissn | 1556-1380 | |
dc.identifier.endpage | S478 | |
dc.identifier.issn | 1556-0864 | |
dc.identifier.issue | 10 | |
dc.identifier.startpage | S477 | |
dc.identifier.uri | https://hdl.handle.net/11452/43443 | |
dc.identifier.volume | 13 | |
dc.identifier.wos | 000454014501235 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Elsevier | |
dc.relation.journal | Journal of Thoracic Oncology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Nsclc | |
dc.subject | Alk inhibitor | |
dc.subject | Crizotinib | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Respiratory system | |
dc.subject | Oncology | |
dc.title | Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey | |
dc.type | Meeting Abstract | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | f971677f-09c5-4463-bf01-3c6341fbe5f7 | |
relation.isAuthorOfPublication.latestForDiscovery | f971677f-09c5-4463-bf01-3c6341fbe5f7 |